Press Releases


  • Cancer therapies MGN1703 and MGN1601 deliver promising study results
  • Start of cooperation with Charité Berlin and Max Delbrück Centrum
  • Successful capital increases create solid financial basis
In the first nine...


At the meeting of the European Society for Medical Oncology (ESMO) detailed results for the colorectal cancer study with the DNA immunomodulator MGN1703 as maintenance therapy were presented today for the first time to an expert audience of clinical...


  • Median overall survival now over 16 months
  • Presentation at the ESMO Meeting in Vienna
Updated data on the overall survival of patients participating in the ASET study was presented within the framework of a scientific...


  • Outstanding study results with cancer therapies MGN1703 and MGN1601
  • Further development of the pipeline through lung cancer study and research cooperation
  • Company’s largest capital increase successfully...


As part of the current capital increase MOLOGEN AG has achieved gross proceeds of 22 million EUR. Overall, 2,589,819 new shares have been placed at an issue price of 8.50 EUR. Existing investors contributed in a significant amount to the capital...


  • Preparation for a phase I/II clinical study with MIDGE®-based gene therapy of malignant melanoma
MOLOGEN AG and the Experimental and Clinical Research Center (ECRC) of Charité – Universitätsmedizin Berlin, and the Max...


  • Expert panel confirms positive results
  • Planning for phase I clinical studies begins
The LEISHDNAVAX consortium*, with MOLOGEN AG as a key partner has successfully concluded the preclinical development of a MIDGE®-based...


Displaying results 1 bis 7 von 13

Page 1

Page 2



Claudia Nickolaus
Head of Investor Relations & Corporate Communications

T. +49 (0) 30 - 84 17 88 - 86
F. +49 (0) 30 - 84 17 88 - 50